Kos, Zuzana
Roblin, Elvire
Kim, Rim S.
Michiels, Stefan
Gallas, Brandon D. http://orcid.org/0000-0001-7332-1620
Chen, Weijie
van de Vijver, Koen K. http://orcid.org/0000-0002-2026-9790
Goel, Shom
Adams, Sylvia
Demaria, Sandra http://orcid.org/0000-0003-4426-0499
Viale, Giuseppe
Nielsen, Torsten O.
Badve, Sunil S. http://orcid.org/0000-0001-8861-9980
Symmans, W. Fraser http://orcid.org/0000-0002-1526-184X
Sotiriou, Christos
Rimm, David L. http://orcid.org/0000-0001-5820-4397
Hewitt, Stephen
Denkert, Carsten
Loibl, Sibylle
Luen, Stephen J.
Bartlett, John M. S.
Savas, Peter http://orcid.org/0000-0001-5999-428X
Pruneri, Giancarlo
Dillon, Deborah A.
Cheang, Maggie Chon U.
Tutt, Andrew
Hall, Jacqueline A. http://orcid.org/0000-0003-0708-1360
Kok, Marleen
Horlings, Hugo M. http://orcid.org/0000-0003-4782-8828
Madabhushi, Anant
van der Laak, Jeroen http://orcid.org/0000-0001-7982-0754
Ciompi, Francesco
Laenkholm, Anne-Vibeke
Bellolio, Enrique http://orcid.org/0000-0003-0079-5264
Gruosso, Tina
Fox, Stephen B.
Araya, Juan Carlos http://orcid.org/0000-0003-3501-8203
Floris, Giuseppe http://orcid.org/0000-0003-2391-5425
Hudeček, Jan http://orcid.org/0000-0003-1071-5686
Voorwerk, Leonie
Beck, Andrew H.
Kerner, Jen
Larsimont, Denis
Declercq, Sabine
Van den Eynden, Gert
Pusztai, Lajos
Ehinger, Anna http://orcid.org/0000-0001-9225-7396
Yang, Wentao
AbdulJabbar, Khalid
Yuan, Yinyin
Singh, Rajendra
Hiley, Crispin
Bakir, Maise al
Lazar, Alexander J. http://orcid.org/0000-0002-6395-4499
Naber, Stephen
Wienert, Stephan
Castillo, Miluska http://orcid.org/0000-0002-0111-3176
Curigliano, Giuseppe http://orcid.org/0000-0003-1781-2518
Dieci, Maria-Vittoria
André, Fabrice
Swanton, Charles
Reis-Filho, Jorge
Sparano, Joseph http://orcid.org/0000-0002-9031-2010
Balslev, Eva
Chen, I-Chun
Stovgaard, Elisabeth Ida Specht
Pogue-Geile, Katherine
Blenman, Kim R. M.
Penault-Llorca, Frédérique
Schnitt, Stuart
Lakhani, Sunil R.
Vincent-Salomon, Anne
Rojo, Federico
Braybrooke, Jeremy P. http://orcid.org/0000-0003-1943-7360
Hanna, Matthew G. http://orcid.org/0000-0002-7536-1746
Soler-Monsó, M. Teresa
Bethmann, Daniel
Castaneda, Carlos A.
Willard-Gallo, Karen http://orcid.org/0000-0002-1150-1295
Sharma, Ashish http://orcid.org/0000-0002-1011-6504
Lien, Huang-Chun
Fineberg, Susan
Thagaard, Jeppe
Comerma, Laura http://orcid.org/0000-0002-0249-4636
Gonzalez-Ericsson, Paula http://orcid.org/0000-0002-6292-6963
Brogi, Edi
Loi, Sherene http://orcid.org/0000-0001-6137-9171
Saltz, Joel
Klaushen, Frederick
Cooper, Lee http://orcid.org/0000-0002-3504-4965
Amgad, Mohamed
Moore, David A.
Salgado, Roberto
Hyytiäinen, Aini
Hida, Akira I.
Thompson, Alastair
Lefevre, Alex
Gown, Allen
Lo, Amy
Sapino, Anna
Moreira, Andre M.
Richardson, Andrea
Vingiani, Andrea
Bellizzi, Andrew M.
Guerrero, Angel
Grigoriadis, Anita
Garrido-Castro, Ana C.
Cimino-Mathews, Ashley
Srinivasan, Ashok
Acs, Balazs
Singh, Baljit
Calhoun, Benjamin
Haibe-Kans, Benjamin
Solomon, Benjamin
Thapa, Bibhusal
Nelson, Brad H.
Ballesteroes-Merino, Carmen
Criscitiello, Carmen
Boeckx, Carolien
Colpaert, Cecile
Quinn, Cecily
Chennubhotla, Chakra S.
Solinas, Cinzia
Drubay, Damien
Sabanathan, Dhanusha
Peeters, Dieter
Zardavas, Dimitrios
Höflmayer, Doris
Johnson, Douglas B.
Thompson, E. Aubrey
Perez, Edith
ElGabry, Ehab A.
Blackley, Elizabeth F.
Reisenbichler, Emily
Chmielik, Ewa
Gaire, Fabien
Lu, Fang-I
Azmoudeh-Ardalan, Farid
Peale, Franklin
Hirsch, Fred R.
Acosta-Haab, Gabriela
Farshid, Gelareh
Broeckx, Glenn
Koeppen, Harmut
Haynes, Harry R.
McArthur, Heather
Joensuu, Heikki
Olofsson, Helena
Cree, Ian
Nederlof, Iris
Frahm, Isabel
Brcic, Iva
Chan, Jack
Ziai, James
Brock, Jane
Weseling, Jelle
Giltnane, Jennifer
Lemonnier, Jerome
Zha, Jiping
Ribeiro, Joana
Lennerz, Jochen K.
Carter, Jodi M.
Hartman, Johan
Hainfellner, Johannes
Le Quesne, John
Juco, Jonathan W.
van den Berg, Jose
Sanchez, Joselyn
Cucherousset, Joël
Adam, Julien
Balko, Justin M.
Saeger, Kai
Siziopikou, Kalliopi
Sikorska, Karolina
Weber, Karsten
Steele, Keith E.
Emancipator, Kenneth
El Bairi, Khalid
Allison, Kimberly H.
Korski, Konstanty
Buisseret, Laurence
Shi, Leming
Kooreman, Loes F. S.
Molinero, Luciana
Estrada, M. Valeria
Van Seijen, Maartje
Lacroix-Triki, Magali
Sebastian, Manu M.
Balancin, Marcelo L.
Mathieu, Marie-Christine
van de Vijver, Mark
Rebelatto, Marlon C.
Piccart, Martine
Goetz, Matthew P.
Preusser, Matthias
Khojasteh, Mehrnoush
Sanders, Melinda E.
Regan, Meredith M.
Barnes, Michael
Christie, Michael
Misialek, Michael
Ignatiadis, Michail
de Maaker, Michiel
Van Bockstal, Mieke
Harbeck, Nadia
Tung, Nadine
Laudus, Nele
Sirtaine, Nicolas
Burchardi, Nicole
Ternes, Nils
Radosevic-Robin, Nina
Gluz, Oleg
Grimm, Oliver
Nuciforo, Paolo
Jank, Paul
Kirtani, Pawan
Watson, Peter H.
Jelinic, Peter
Francis, Prudence A.
Russell, Prudence A.
Pierce, Robert H.
Hills, Robert
Leon-Ferre, Roberto
de Wind, Roland
Shui, Ruohong
Leung, Samuel
Tabbarah, Sami
Souza, Sandra C.
O’Toole, Sandra
Swain, Sandra
Dudgeon, Sarah
Willis, Scooter
Ely, Scott
Bedri, Shahinaz
Irshad, Sheeba
Liu, Shiwei
Hendry, Shona
Bianchi, Simonetta
Bragança, Sofia
Paik, Soonmyung
Luz, Sua
Gevaert, Thomas
d’Alfons, Timothy
John, Tom
Sugie, Tomohagu
Kurkure, Uday
Bossuyt, Veerle
Manem, Venkata
Cámaea, Vincente Peg
Tong, Weida
Tran, William T.
Wang, Yihong
Allory, Yves
Husain, Zaheed
Bago-Horvath, Zsuzsanna
,
Funding for this research was provided by:
Breast Cancer Research Foundation (17-194)
Article History
Received: 21 July 2019
Accepted: 2 March 2020
First Online: 12 May 2020
Competing interests
: A.E. is on the Roche advisory board and has reported honoraria from Amgen, Novartis and Roche. A.J.L. is a consultant for BMS, Merck, AZ/Medimmune, and Genentech. R.S. reports research funding from Roche, Puma, Merck; advisory board and consultancy for BMS; travel funding from Roche, Merck, and Astra Zeneca. S.G. reports Lab research funding from Lilly, Clinical research funding from Eli Lilly and Novartis and is a Paid advisor to Eli Lilly, Novartis, and G1 Therapeutics. J.v.d.L. is member of the scientific advisory boards of Philips, the Netherlands and ContextVision, Sweden and receives research funding from Philips, the Netherlands and Sectra, Sweden. S.A. reports Research funding to institution from Merck, Genentech, BMS, Novartis, Celgene and Amgen and is an uncompensated consultant /steering committee member for Merck, Genentech and BMS. T.O.N. has consulted for Nanostring and received compensation and has intellectual property rights/ownership interests from Bioclassifier LLC [not related to the subject material under consideration]. S.L. receives research funding to institution from Novartis, Bristol Meyers Squibb, Merck, Roche-Genentech, Puma Biotechnology, Pfizer and Eli Lilly, has acted as consultant (not compensated) to Seattle Genetics, Pfizer, Novartis, BMS, Merck, AstraZeneca and Roche-Genentech and acted as consultant (paid to her institution) to Aduro Biotech. S.R.L. has received travel and educational funding from Roche/Ventana. A.M. is an equity holder in Elucid Bioimaging and in Inspirata Inc., a scientific advisory consultant for Inspirata Inc, has served as a scientific advisory board member for Inspirata Inc, Astrazeneca, Bristol Meyers-Squibb and Merck, has sponsored research agreements with Philips and Inspirata Inc, is involved in a NIH U24 grant with PathCore Inc, and 3 different R01 grants with Inspirata Inc. and his technology has been licensed to Elucid Bioimaging and Inspirata Inc. G.C. is on the advisory boards of Roche, BMS, Pfizer, Seattle Genetics and Ellipsis, and reports personal fees from Roche, BMS, Pfizer, Seattle Genetics, and Ellipsis, outside of the submitted work. J.H. is the director and owner of Vivactiv Ltd. J.H. is the director and owner of Slide Score B.V. F.P.L. reports funding from Astrazeneca, BMS, Roche, MSD, Pfizer, Novartis, Sanofi, Eli Lilly. J.B. reports consultancies from Insight Genetics, BioNTech AG, Biotheranostics, Pfizer, RNA Diagnostics and OncoXchange, research funding from Thermo Fisher Scientific, Genoptix, Agendia, NanoString Technologies, Stratifyer GmbH and Biotheranostics, applied for patents, including Jan 2017: Methods and Devices for Predicting Anthracycline Treatment Efficacy, US utility—15/325,472; EPO—15822898.1; Canada—not yet assigned; Jan 2017: Systems, Devices and Methods for Constructing and Using a Biomarker, US utility—15/328,108; EPO—15824751.0; Canada—not yet assigned; Oct 2016: Histone gene module predicts anthracycline benefit, PCT/CA2016/000247; Dec 2016: 95‐Gene Signature of Residual Risk Following Endocrine Treatment, PCT/CA2016/000304; Dec 2016: Immune Gene Signature Predicts Anthracycline Benefit, PCT/CA2016/000305. M.A.S. reports consulting work for Achilles Therapeutics. C.S. reports receipt of grants/research support from Pfizer, AstraZeneca, BMS and Ventana; receipt of honoraria, consultancy, or SAB Member fees from Pfizer, Novartis, GlaxoSmithKline, MSD, BMS, Celgene, AstraZeneca, Illumina, Sarah Canon Research Institute, Genentech, Roche-Ventana, GRAIL, Medicxi; Advisor for Dynamo Therapeutics; Stock shareholder in Apogen Biotechnologies, Epic Bioscience, GRAIL; Co-Founder & stock options in Achilles Therapeutics. A.H.B. is the co-founder and CEO of PathAI. J.K. is an employee of PathAI. D.D. is on the advisory board for Oncology Analytics, Inc, and a consultant for Novartis. D.L.R. is on the advisory board of Amgen, Astra Zeneca, Cell Signaling Technology, Cepheid, Daiichi Sankyo, GSK, Konica/Minolta, Merck, NanoString, Perkin Elmer, Ventana, Ultivue; receives research support from Astra Zeneca, Cepheid, Navigate BioPharma, NextCure, Lilly, Ultivue; instrument support from Ventana, Akoya/Perkin Elmer, NanoString; paid consultant for Biocept; received travel honoraria from BMS, founder and equity holder for PixelGear and received royalty from Rarecyte. A.T. reports benefits from ICR’s Inventors Scheme associated with patents for one of PARP inhibitors in BRCA1/2 associated cancers, as well as honoraria from Pfizer, Vertex, Prime Oncology, Artios, honoraria and stock in InBioMotion, honoraria and financial support for research from AstraZeneca, Medivation, Myriad Genetics and Merck Serono. This work includes contributions from, and was reviewed by, individuals at the FDA. This work has been approved for publication by the agency, but it does not necessarily reflect official agency policy. Certain commercial materials and equipment are identified in order to adequately specify experimental procedures. In no case does such identification imply recommendation or endorsement by the FDA, nor does it imply that the items identified are necessarily the best available for the purpose. This work includes contributions from, and was reviewed by, individuals who received funding from the National Institutes of Health, the U.S. Department of Veterans Affairs and the Department of Defense. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health, the U.S. Department of Veterans Affairs, the Department of Defense, or the United States Government.